Jaume Capdevila

🧬 Pancreatic NETs & nodal staging 📊 68Ga-DOTATATE PET • Sensitivity 46% → misses LN+ • Specificity 92% → positives reliable 🔎 Positive = likely true ⚠️ Negative ≠ exclude disease 💡 Useful to confirm nodal involvement, but limited to rule it out 🔗 doi.org/10.1016/j.surg…

#RAS #revolution in first line chemo combo with gemcitabine and nab-paclitaxel backbone, the preview for ongoing registrational RASolute 303 study #KRAS #PDAC @MSK_DeptOfMed @MSKCancerCenter

Happy to share our new #multicentre international collaborative study on clinical predictors of outcome in advanced #adrenocorticalcarcinoma #ACC. @ENSAT_news @ESEndocrinology @EJEndo #raredisease #chemotherapy #adrenalcancer #prognostictool @LetsCureAcc #557659058" target="_blank" rel="nofollow noopener">academic.oup.com/ejendo/article…

📢 4º Curso Teórico-Práctico de Diagnóstico en Patología Tiroidea 📍 Santiago de Compostela | 8–10 julio 2026 👨‍🏫 Directores: Cameselle-Teijeiro, Abdulkader Nallib & Sobrinho-Simões 🎯 Focus: papel del patólogo en la identificación de dianas terapéuticas 🔗 Programa e inscripción: idisantiago.es/event/4o-curso…

A must-read review on KRAS inhibitors! 🔗doi.org/10.1016/j.ccel… @Cancer_Cell @OncoAlert

Emerging landscape of KRAS inhibitors in cancer treatment dlvr.it/TRSSmx

Could pancreatic cancer be prevented (before it starts)? Most pancreatic cancers arise from KRAS-mutant precursor lesions — it would make sense that inhibiting KRAS could intercept progression That was tested here (in mice!) — KRAS inhibition reduced the burden of precursor lesions and delayed progression to pancreatic cancer The inhibitors from Revolution Medicines were used (who already have multiple phase 3 trials running for KRAS inhibitors in established pancreatic cancer) Key questions here to move it forwards in humans: 1) We'll need a much better test to detect these precursor lesions (which usually go undetected, and are generally not visible on standard imaging) 2) Most precursor lesions never progress, so how do we identify the lesions at genuinely high risk? 3) Would people with these precursors — who are asymptomatic — tolerate the side-effects of KRAS inhibitors?

🆕 @ScienceMagazine An exciting new approach vs pancreatic cancer: "cancer interception" Considered ubiquitous, the pancreas in healthy adults has hundreds of PanINs of microscopic premalignant cancer that can be regressed in the experimental model science.org/doi/10.1126/sc… science.org/doi/10.1126/sc…

KRAS inhibitors have been used to treat pancreatic cancer, but can they PREVENT cancer from occurring altogether? In @ScienceMagazine from @PennCancer Cancer interception with KRAS inhibitors in preclinical models of #PancreaticCancer science.org/doi/10.1126/sc…

Next-generation KRAS G12C inhibitor olomorasib shows promising pan-tumor activity in a first-in-human study. ORR ~37% in non-CRC tumors with durable response. Activity even observed after prior KRAS G12C inhibitors. KRAS targeting keeps evolving. nature.com/articles/s4146…

🧬 MSI-H/dMMR cholangiocarcinoma 📍 Real-world propensity-matched study (JHEP Reports) 👥 331 pts | MSI-H/dMMR: 6.9% 📊 ICIs-based therapy • mPFS 64.1 vs 7.2 mo • mOS 70.5 vs 14.0 mo (vs MSS) 🎯 MSI-H/dMMR emerges as a key predictive biomarker 🔗 doi.org/10.1016/j.jhep… @GrupoTTD @OncoAlert

Clinical approach to the care of patients with recurrent differentiated thyroid cancer: a focus on papillary thyroid carcinoma - Endocrine Practice endocrinepractice.org/article/S1530-…

Platelets fall just before the next oxaliplatin-based chemotherapy. What now? In a ph3 trial of GI cancers receiving oxaliplatin based ChT, Romiplostim allowed 84% of pts to continue ChT vs 36% with placebo; now in @NEJM nejm.org/doi/full/10.10…

📍 Recordatorio | Campus GETNE 2026 🗓️ 16–17 abril 📍 Barcelona 🧬 Actualización, debate y casos clínicos en tumores neuroendocrinos y endocrinos 🤝 Nos vemos en #CampusGETNE26

📄 Nuevo case report Lorlatinib mostró respuesta clínica en un carcinoma tiroideo pobremente diferenciado con reordenamiento ALK, tras progresión a un TKI previo dirigido a ALK. @yaringano_jesus @JHernando3 @Ja_Capdevila @vallhebron @VHIO

This might be the largest study of QOL in patients with NETs, the NET-PRO study -- 2,367 participants from multiple US centers (mean age 57.8 years; 57.3% female) -- 1,974 with GEP-NETs (659 SI-NET, 555 pNET) and 393 with lung NETs -- Fatigue (mean 33.0), insomnia (32.5), and diarrhea (25.7) were the most burdensome symptoms -- Lung NET patients reported worse dyspnea (SMD = 0.58, p < 0.001) and lower physical, role, and global QoL scores than those with GEP-NETs -- Diarrhea worsened over time, especially in SI-NETs. --- Most rated care highly (75.3%) but cited concerns about treatment side effects (80.4%), costs (60.7%), and travel burden (58.8%). Very informative and more is on its way from this group. Thanks to the NET-PRO group for this herculean effort which is still ongoing. academic.oup.com/jnci/advance-a…

I learned so much writing this review of novel PDAC therapies with my brilliant mentors @EileenMOReilly & @CentralParkWMD. Amazing to have multiple targeted therapies with single agent activity. It's a great time to start a career in PDAC drug development. link.springer.com/article/10.100…

Time for another NET talk - this time on sequencing of systemic therapy. Another excellent @MayoMedEd offering. If you are looking for a good course in pretty much anything in Med Ed, check them out. They have a huge selection of quality courses, not just in oncology. So how to we select initial therapy for advanced NETs when resection or other regional therapy is not a good option...? Below are some thoughts, as always open to criticism and and comments (snarky comments also welcomed if you feel so inclined...). Come join us for future Mayo Clinic conferences!

📣@GgnetGrupo PRRT consensus in NETs is published! ✔️ PRRT for progressive SSTR+ GEP-NETs (G1–G3, Ki-67 ≤55%) 📌 SSTR-PET essential for patient selection 🔎 FDG-PET adds prognostic value 🎯 Practical guidance to harmonize PRRT selection, treatment and follow-up Proud to lead this work! 🔗 doi.org/10.1007/s12094… @OncoAlert

It all started with a @GrupoGetne Galicia meeting in Santiago de Compostela in 2020, proposed by @Ja_Capdevila. From that conversation, the idea of creating @GgnetGrupo was born. Today that seed has grown into our first consensus on PRRT in NETs Thank you for the inspiration.